Explore the capabilities of the Pin-point™ base editing platform, designed for precise, multiplex gene editing in human T cells and iPSCs. Our white paper provides an in-depth analysis of how this technology enables targeted genetic modifications with improved safety compared to traditional methods. Key highlights include:

• High-efficiency Multiplex Editing: Achieve simultaneous gene modifications in clinically relevant cell types.
• Enhanced Safety Profile: Minimize off-target effects and chromosomal translocations.
• Comprehensive Single-Cell Analysis: Leverage CITE-Seq to assess the functional impact of gene edits.

Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity with further development from the licensee.

For research use only. Not for use in diagnostic procedures